Sanofi ($SNY) CEO Chris Viehbacher is betting that an experimental liver cancer drug could make big inroads in China. The company is going ahead with the first human trials of the drug next year. Report
Sanofi ($SNY) CEO Chris Viehbacher is betting that an experimental liver cancer drug could make big inroads in China. The company is going ahead with the first human trials of the drug next year. Report